Mologic Ltd.
Registered name: MOLOGIC LTD.
Part of Global Access Health groupMologic Ltd. does not publish its revenue or profit. Its accounts to 30 Jun 2026 show net assets of £286k and 45 employees.
Mologic Ltd. did not publish its revenue or profit — small companies aren’t required to file a profit & loss account. Its accounts for the year to 30 Jun 2026 showed net assets of £286k and 45 employees. The company is classified under “research and experimental development on biotechnology” and is based in Bedford; we hold 5 years of its filed accounts.
- Status
- Active
- Location
- Bedford, South East
- Age
- 23 yrs · since 2003
- Type
- Private Limited Company
Part of a group. The filing indicates this company sits within a group structure, so its results may depend on intra-group trading and it may be hard to replicate independently.
Key figures
Revenue not disclosed
Mologic Ltd.’s accounts for the year to 30 Jun 2026 contain a balance sheet but no profit & loss account, so its revenue and profit are not public. UK small and micro-entity companies are not required to publish a P&L — this is normal and says nothing about how the business is performing.
We never estimate revenue. Below you’ll find the balance-sheet figures that were filed — useful as indirect signals of momentum, but they are not revenue or profit.
- Employees
- 45
- Net assets
- £286k
Badges are automated estimates derived from the filed figures — not statements of fact about the company.
Financial history
| Year to | 30 Jun 2022 | 30 Jun 2023 | 30 Jun 2024 | 30 Jun 2025 | 30 Jun 2026 |
|---|---|---|---|---|---|
| Disclosure | Full P&L | Full P&L | Full P&L | Full P&L | No P&L |
| Profit & loss | |||||
| Revenue (turnover) | £9.1m | £4.2m | £4.9m | £2.3m | — |
| Cost of sales | £3.9m | £547k | £555k | £907k | — |
| Gross profit | £5.2m | £3.6m | £4.3m | £1.4m | — |
| Operating profit | −£403k | −£856k | £927k | −£3.4m | — |
| Profit before tax | −£1.7m | −£1.3m | £942k | −£3.4m | — |
| Profit after tax | −£1.9m | −£963k | £576k | −£2.7m | — |
| Profit (best available) | −£1.9m | −£963k | £576k | −£2.7m | — |
| Staff costs | £7.6m | £4.4m | £3.6m | £3.7m | — |
| Employees (average) | 81 | 65 | 55 | 60 | 45 |
| Ratios | |||||
| Profit margin | −21.5% | −23% | 11.8% | −115.8% | — |
| Gross margin | 57.4% | 86.9% | 88.7% | 61.2% | — |
| Revenue per employee | £112k | £64.3k | £89.1k | £38.9k | — |
| Profit per employee | −£24k | −£14.8k | £10.5k | −£45k | — |
| Growth (year on year) | |||||
| Revenue growth | — | — | ▲17.2% | ▼52.4% | — |
| Profit growth | — | — | — | ▼569.4% | — |
| Headcount growth | — | — | ▼15.4% | ▲9.1% | ▼25% |
| Balance sheet — indirect signals, not revenue | |||||
| Cash at bank | £2.4m | £162k | £664k | £168k | £286k |
| Net assets | £2.3m | £1.3m | £1.9m | £1.3m | £286k |
| Fixed assets | £1.8m | £2.1m | £2m | £324k | £143k |
| Current assets | £4.3m | £2.8m | £2.6m | £1.9m | £1.3m |
| Debtors | £1.3m | £656k | £1m | £248k | £293k |
| Deferred income | £3.3m | £1.2m | £729k | £477k | £534k |
| Source | FullAccounts · bulk data Apr 2024 | FullAccounts · bulk data Apr 2024 | FullAccounts · bulk data Mar 2025 | FullAccounts · bulk data Mar 2026 | FullAccounts · bulk data Aug 2026 |
Balance-sheet signals
Year-on-year changes in filed balance-sheet items. They can hint at momentum (or investment) but are not revenue or profit and must not be read as such.
- Net assets
- ▼77%
- Now £286k
- Cash at bank
- ▲70%
- Now £286k
- Headcount
- ▼25%
- Now 45
- Deferred income
- ▲12%
- Now £534k
- Fixed assets
- ▼56%
- Now £143k
Deferred income is reported together with accruals in this filing (“accruals and deferred income”), so it is an approximate signal only.
Group structure
Ownership chain
- Global Access Healthultimate parent75–100%
- Mologic Ltd.this company
Bands show the share of ownership each company holds in the one below it.
From the Persons with Significant Control register (corporate controllers only).
Similar profitable businesses
- Astex Therapeutics LimitedCambridge · Research and experimental development on biotechnology
- Revenue
- £404m
- Profit
- £283m
- Staff
- 183
- Amphista Therapeutics LimitedCambridge · Research and experimental development on biotechnology
- Revenue
- £33.9m
- Profit
- £19.8m
- Staff
- 56
- Charles River U.K. LimitedKent · Research and experimental development on biotechnology
- Revenue
- £22.2m
- Profit
- £18.8m
- Staff
- 129
- Qiagen Manchester LimitedManchester · Research and experimental development on biotechnology
- Revenue
- £53.7m
- Profit
- £11.8m
- Staff
- 239
- Alchemab Therapeutics LtdLondon · Research and experimental development on biotechnology
- Revenue
- £30m
- Profit
- £8.3m
- Staff
- 55
- Ligand UK Development LimitedLondon · Research and experimental development on biotechnology
- Revenue
- £8.7m
- Profit
- £6m
- Staff
- —
Sources
Latest figures from FullAccounts for the year to 30 Jun 2026, from the Companies House accounts bulk data published Aug 2026. Spotted an error? Request a correction.
Contains public sector information from Companies House licensed under the Open Government Licence v3.0. Data from Companies House, © Crown copyright. View the licence.